About Therakos
Therakos is a company based in West Chester (United States) founded in 1984 was acquired by CVC in August 2024. It operates as a HealthTech and Direct-to-Consumer (D2C). Therakos offers products and services including THERAKOS CELLEX Photopheresis System and UVADEX (methoxsalen) Sterile Solution. Therakos operates in a competitive market with competitors including SetPoint Medical, Aura Biosciences, Philogen, OnQuality and Boomerang Medical, among others.
- Headquarter West Chester, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Therakos Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Therakos
Therakos offers a comprehensive portfolio of products and services, including THERAKOS CELLEX Photopheresis System and UVADEX (methoxsalen) Sterile Solution.
Used for palliative treatment of CTCL skin manifestations.
Administered extracorporeally for CTCL skin symptom treatment.
Funding Insights of Therakos
Detailed funding history for Therakos
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Therakos
Therakos has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include CVC, Mallinckrodt Pharmaceuticals and The Gores Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Mezzanine financing and equity investments are provided by CVC.
|
Locked | Locked | Locked | |
|
Private investments are made in mature businesses across multiple sectors.
|
Locked | Locked | Locked | |
|
Specialty pharmaceutical products and diagnostic imaging agents are manufactured.
|
Locked | Locked | Locked |
Investor details for Therakos
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Therakos
Investment portfolio details for Therakos
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Therakos
Detailed financials for Therakos
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Therakos Comparisons
Peer comparison for Therakos
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Therakos
Therakos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SetPoint Medical, Aura Biosciences, Philogen, OnQuality and Boomerang Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Implantable neuromodulation devices are developed for inflammatory diseases.
|
|
| Locked | Locked | Locked |
Therapies are developed to target and destroy cancer cells selectively.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for angiogenesis-related cancers and disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for skin cancers and related reactions are developed.
|
|
| Locked | Locked | Locked |
Bioelectronic devices are developed for autoimmune disease treatment.
|
|
| Locked | Locked | Locked |
Developer of a medical device to provide an automated test that detects allergies
|
Detailed competitors of Therakos
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Therakos
Complete news archive for Therakos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Therakos
Therakos was founded in 1984.
Therakos is headquartered in West Chester, United States. It is registered at West Chester, Pennsylvania, United States.
Therakos is engaged in providing photopheresis solutions for the palliative treatment of cutaneous T-cell lymphoma (CTCL) skin manifestations. The company offers the THERAKOS CELLEX Photopheresis System and UVADEX (methoxsalen) Sterile Solution, targeting healthcare professionals in the United States. Services are extended through customer support, professional resources, and the Therakos Institute to build a community of expert operators. The focus is placed on the healthcare sector, specifically in dermatological and oncological treatment solutions.
Therakos's top competitors include Philogen, SetPoint Medical and Aura Biosciences.
Therakos offers THERAKOS CELLEX Photopheresis System and UVADEX (methoxsalen) Sterile Solution.
Therakos has 3 investors. Key investors include CVC, Mallinckrodt Pharmaceuticals, and The Gores Group.